Merus to Present at Upcoming Investor Conferences
Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company specializing in multispecific antibodies, has announced its participation in two upcoming investor conferences. Bill Lundberg, M.D., President and CEO, will participate in a fireside chat at the Guggenheim Securities Healthcare Innovation Conference on Tuesday, November 12 at 9:30 a.m. ET and at the Stifel 2024 Healthcare Conference on Monday, November 18 at 3:00 p.m. ET. Both presentations will be available via webcast on the company's website's Investors page, with archived versions accessible for a time afterward.
Merus N.V. (Nasdaq: MRUS), un'azienda oncologica in fase clinica che si specializza in anticorpi multispecifici, ha annunciato la sua partecipazione a due prossime conferenze per investitori. Bill Lundberg, M.D., Presidente e CEO, parteciperà a una chiacchierata informale alla Guggenheim Securities Healthcare Innovation Conference martedì 12 novembre alle 9:30 ET e alla Stifel 2024 Healthcare Conference lunedì 18 novembre alle 15:00 ET. Entrambe le presentazioni saranno disponibili in diretta streaming sulla pagina Investitori del sito web dell'azienda, con versioni registrate accessibili successivamente.
Merus N.V. (Nasdaq: MRUS), una empresa de oncología en etapa clínica que se especializa en anticuerpos multispecíficos, ha anunciado su participación en dos próximas conferencias para inversores. Bill Lundberg, M.D., Presidente y CEO, participará en una charla informal en la Guggenheim Securities Healthcare Innovation Conference el martes 12 de noviembre a las 9:30 a.m. ET y en la Stifel 2024 Healthcare Conference el lunes 18 de noviembre a las 3:00 p.m. ET. Ambas presentaciones estarán disponibles a través de webcast en la página de Inversores del sitio web de la empresa, con versiones archivadas accesibles posteriormente.
Merus N.V. (Nasdaq: MRUS)는 다중 특이성 항체를 전문으로 하는 임상 단계의 종양학 회사로, 두 개의 다가오는 투자자 컨퍼런스에 참여할 것이라고 발표했습니다. Bill Lundberg, M.D., 사장 겸 CEO는 11월 12일 화요일 오후 9시 30분 ET에 Guggenheim Securities Healthcare Innovation Conference에서 열리는 화로 이야기(fireside chat)에 참여하고, 11월 18일 월요일 오후 3시 ET에 Stifel 2024 Healthcare Conference에도 참석할 예정입니다. 두 발표는 회사 웹사이트의 투자자 페이지에서 웹캐스트로 제공되며, 이후에 아카이브 버전도 접근할 수 있습니다.
Merus N.V. (Nasdaq: MRUS), une entreprise d'oncologie en phase clinique spécialisée dans les anticorps multis spécifiques, a annoncé sa participation à deux prochaines conférences pour investisseurs. Bill Lundberg, M.D., Président et CEO, participera à une discussion informelle lors de la Guggenheim Securities Healthcare Innovation Conference le mardi 12 novembre à 9h30 ET et à la Stifel 2024 Healthcare Conference le lundi 18 novembre à 15h00 ET. Les deux présentations seront disponibles en webdiffusion sur la page des Investisseurs du site Web de l'entreprise, avec des versions archivées accessibles par la suite.
Merus N.V. (Nasdaq: MRUS), ein klinisches Unternehmen in der Onkologie, das sich auf multispezifische Antikörper spezialisiert hat, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen angekündigt. Bill Lundberg, M.D., Präsident und CEO, wird an einem informellen Gespräch auf der Guggenheim Securities Healthcare Innovation Conference am Dienstag, den 12. November um 9:30 Uhr ET und an der Stifel 2024 Healthcare Conference am Montag, den 18. November um 15:00 Uhr ET teilnehmen. Beide Präsentationen werden über ein Webcast auf der Investoren-Seite der Unternehmenswebsite verfügbar sein, mit archivierten Versionen, die später zugänglich sind.
- None.
- None.
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in the following investor conferences:
- Guggenheim Securities Healthcare Innovation Conference (fireside chat): Tuesday, November 12 at 9:30 a.m. ET
- Stifel 2024 Healthcare Conference (fireside chat): Monday, November 18 at 3:00 p.m. ET
The webcasts of the presentations will be contemporaneously available on the Investors page of the Company's website. The archived presentations will also be available there for a limited time after the event.
About Merus
Merus is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics®. Multiclonics® are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. For additional information, please visit Merus’ website, X and LinkedIn.
Multiclonics®, Biclonics® and Triclonics® are registered trademarks of Merus N.V.
FAQ
When is Merus (MRUS) presenting at the Guggenheim Securities Healthcare Innovation Conference?
When is Merus (MRUS) presenting at the Stifel 2024 Healthcare Conference?
Where can investors watch Merus (MRUS) investor conference presentations?
Who will represent Merus (MRUS) at the upcoming investor conferences?
